share_log

Needham Reiterates Buy on G1 Therapeutics, Maintains $14 Price Target

Benzinga ·  Dec 6, 2023 05:16

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $14 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment